ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Stock-based compensation by Year
Stock-based compensation — Allocated income tax benefit ($M) ($M)
Eli Lilly Stock-based compensation: $626M in FY2025, down 3.1% from a year earlier.
Latest, FY2025
626
Period ended Dec 31, 2025
Change on a year earlier
-3.1%
646 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-12) ↗
Reported in Form 10-K Stock-Based Compensation Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Stock-based compensation — Allocated income tax benefit ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 626 | -3.1% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 646 | +2.7% | Form 10-K (filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 629 | +69.5% | Form 10-K (filed 2026-02-12) ↗ |
| FY2022 | Dec 31, 2022 | 371 | +8.3% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 343 | +11.3% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 308 | +0.4% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 307 | +21.0% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 254 | -1.1% | Form 10-K (filed 2021-02-17) ↗ |
| FY2017 | Dec 31, 2017 | 256 | +0.4% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 255 | – | Form 10-K (filed 2019-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Stock-based compensation ($M), annual FY2016–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/sbc-tax-benefit
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.